Corporate Vision March 2017

CORPORATE VISION / March 2017 75 , Fernand Labrie is CEO of Endoceutics and recently received the CEO of theMonth- Canada (Pharma) award. In an interview, he tells us more about the company and how it plans to change the lives of women the world over. Innovation for Women’s Health Endoceutics is a private pharmaceutical company operating in the field of women’s health and hormone-sensitive cancer prevention and treatment. Following approval by the FDA of Intrarosa™ in November 2016, for the treatment of dyspareunia, a symptom of vulvovaginal atrophy due to menopause, Endoceutics focuses on developing non estrogen-based therapies for sexual dysfunction and the other symptoms of menopause, including hot flushes, osteoporosis, muscle loss and type 2 diabetes. Hormonal therapies for breast, uterine and prostate cancer, male hypogonadism as well as endometriosis are also under development. Endoceutics has five Phase III product candidates addressing large market opportunities and two Phase I/II product candidates. Endoceutics has exclusive worldwide rights to patents, patent applications, technology and know-how related to all its products. Fernand Labrie is Chief Executive Officer at Endoceutics and he explains that the company’s key principle is innovation in science. “Our business goes from fundamental discovery to clinical research, manufacturing and commercialisation or a complete pharmaceutical company,” “We provide novel treatments using the latest science and technology applied to all aspects of menopause.” Fernand Labrie has been awarded CEO of the Month for his dedication and his role in the industry. He tells us how it felt to receive this prestigious accolade, and what key attributes he believes make him an award- winning leader. “It is great to see that all the work performed by such a large number of colleagues over so many years in order to develop the new science of intracrinology becomes known and can be applied to women. “With the collaboration, expertise and dynamism of hundreds of colleagues, we could discover and develop a completely new field, namely intracrinology, which is behind this innovative new treatment for women’s health. We previously discovered and developed the first treatment to prolong life in prostate cancer and the first combination therapy approved by any health authority (1984 in Canada and 1989 in the US). “There are many challenges since much patience is needed to start from discovery and apply the interesting discoveries up to the patient. One of the challenges is all the steps which we have to go through up to the FDA, Health Canada and other Health Agency approvals. Also, one of the biggest challenges in research and development is to find investment and people who believe in your project, which is not easy.” Fernand Labrie foresees continuing success and growth for Endoceutics and tells us why there are exciting times ahead for both the firm and the industry. “Looking to the future, we believe that the female health market will be dominated by a focus on creating novel treatments for all aspects of menopause based upon intracrinology or the normal physiology of sex steroids, a discovery of Endoceutics. In order to keep ahead of this emerging development, we will be seeking to explore more clinical applications using the best technology which we largely developed, taking as example steroid assays using mass spectrometry, now the gold standard in the industry. Change in the therapeutic field is central to improving the lives of women across the globe, and as such, we will continue to embrace this strategy as we seek to remain the leaders of innovation in the women’s health pharmaceutical market. “Our overall aim is to be able to offer to all women around the world the benefits of an efficacious and safe treatment of all the problems of menopause, which include hot flushes, vaginal dryness, sexual dysfunction, loss of bone, loss of muscle as well as memory and cognition loss. We have a strong desire to move science forward for a better life of our fellow citizens, and this will remain our ongoing goal. “Moving forward, we see exciting times ahead as Endoceutics is bringing IntrarosaTM to market with partners and consequently change the lives of millions of women around the world.” K Company: Endoceutics™ Name: Fernand Labrie Email: [email protected] Web Address: www.endoceutics.com Address: Endoceutics 2795 boul. Laurier, suite 500 Quebec (QC) G1V 4M7 Telephone: +1 418 653 0033 1703CV12